Forty-three days separated AVLAYAH’s FDA accelerated approval from first commercial patient dosing — a logistical sprint that matters less for what it says about Denali’s operational execution and more for what it reveals about the clinical pressure now bearing down on the program. Accelerated approval for the neurologic manifestations of Hunter syndrome came with the standard condition: a confirmatory trial must verify clinical benefit, or the approval evaporates. That confirmatory vehicle is the global Phase 2/3 COMPASS study, and its success or failure will determine whether AVLAYAH becomes a durable franchise or an expensive proof-of-concept.

The more scientifically consequential news is buried beneath the commercial launch update. In March, Denali dosed the first patient in the Phase 1b study of DNL628, an oligonucleotide therapy designed to cross the blood-brain barrier via its OTV platform and silence MAPT — the gene encoding tau. This is not an antibody targeting aggregated tau after the fact; it is a gene-silencing approach aimed at reducing tau production upstream, before pathological accumulation. Every major tau antibody program has failed in symptomatic Alzheimer’s populations. DNL628’s hypothesis is that the failure mode was biological timing and inadequate CNS penetration, not the target itself. The OTV platform is the untested variable, and Phase 1b data expected in the first half of 2027 will be the first real read on whether the transport mechanism delivers meaningful MAPT suppression in humans.

Also structurally significant: Takeda terminated its co-development agreement on DNL593, the progranulin replacement therapy for GRN-related frontotemporal dementia. Takeda explicitly attributed the decision to internal strategic priorities, not to efficacy or safety signals. That distinction matters. Enrollment in the Phase 1/2 study closed at 40 participants, and Denali retained full rights, supported by the $200 million it raised through a synthetic royalty agreement with Royalty Pharma. The company is not scrambling — it has the capital and the data timeline. Results are expected by year-end 2026.

The single marker worth tracking closely is the COMPASS study design and its primary endpoint. Accelerated approval for AVLAYAH rested on a biomarker surrogate; confirmatory benefit must be demonstrated in actual neurologic outcomes. How Denali defines and powers that endpoint will determine both the regulatory durability of its first commercial product and the credibility of the TransportVehicle platform across every program that follows.

Source link: https://www.globenewswire.com/news-release/2026/05/07/3290512/0/en/Denali-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Highlights.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.